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1 
METHOD OF TREATING PARKINSON’S 
DISEASE IN HUMANS BY 
CONVECTION-ENHANCED INFUSION OF 
GLIAL CELL-LINE DERIVED 
NEUROTROPHIC FACTOR TO THE 
PUTAMEN 
This application was ?led as a US. National Phase Appli 
cation pursuant to 35 U.S.C. §371 of International Applica 
tion No. PCT/US2005/034347 which was ?led Sep. 22, 2005, 
which is a continuation-in-part of US. application Ser. No. 
10/784,547 which was ?led Feb. 23, 2004, which in turn 
claims bene?t under 35 U.S.C. §119 ofU.S. Application Ser. 
No. 60/499,317 which was ?led Feb. 24, 2003. The entire 
disclosure of each of the foregoing applications is incorpo 
rated herein by reference in its entirety. 
FIELD OF THE INVENTION 
The present invention relates generally to the ?eld of neu 
robiology. More particularly, it concerns methods for treating 
Parkinson’ s disease in humans and related methods of restor 
ing atrophic dopaminergic neurons and protecting dopamin 
ergic neurons at risk of degeneration are also described. 
This application contains, as a separate part of disclosure, 
a Sequence Listing in computer-readable form (?lename: 
40551A_SeqListing_ST25.txt; crated Apr. 7, 2011; 7,743 
bytesiASCII text ?le) which is incorporated by reference in 
its entirety. 
BACKGROUND OF THE INVENTION 
Current treatments for Parkinson’s disease (PD) become 
increasingly less ef?cacious as the disease progresses, and do 
little to slow the underlying pathophysiological changes in 
the nigrostriatal dopaminergic system (Rascol, O., et al., 
Limitations of Current Parkinson’s Disease Therapy, Ann. 
Neurol., 53 Suppl 3:S3-12 (2003); Romell, 1., et al., Rationale 
for Current Therapies in Parkinson’s Disease, Expert Opin. 
Pharmacother., 4:1747-1761 (2003)). Neurotrophic factors, 
proteins which activate cell signaling pathways regulating 
neuronal survival, differentiation, growth and regeneration, 
offer promising therapy for treating dopamine neurons in PD, 
but are dif?cult to administer clinically as they do not pass 
through the blood brain barrier (Beck, K. D., et al., Mesen 
cephalic Dopaminergic Neurons Protected by GDNF from 
Axotomy-Induced Degeneration in the Adult Brain, Nature, 
373:339-3416 (1995); Bjorklund, A., et al., Towards a Neu 
roprotective Gene Therapy for Parkinson’s Disease: Use Of 
Adenovirus, AAV and Lentivirus Vectors for Gene Transfer of 
GDNF to the Nigrostriatal System in the Rat Parkinson 
Model, Brain Res., 886:82-98 (2000)). Glial cell line-derived 
neurotrophic factor (GDNF) is a trophic factor shown to 
dramatically protect and enhance the function of dopamine 
neurons in vitro and in vivo in rodents and monkeys (Beck, K. 
D., et al., (1995); Bjorklund,A., et al., (2000); Gash, D. M., et 
al., Functional Recovery in Parkinsonian Monkeys Treated 
with GDNF, Nature, 380:252-255 (1996); Grondin, R., et al., 
Striatal GDNF Infusion Promotes Structural and Functional 
Recovery in Advanced Parkinsonian Monkeys. Brain, 125: 
2191-2201 (2002); Grondin, R., et al., GDNF Increases 
Stimulus-evoked Dopamine Release and Motor Speed in 
Aged Rhesus Monkeys, J. Neurosci., 23:1974-1980 (2003); 
Hebert M. A., et al., Functional Effects of GDNF in Normal 
Rat Striatum: Presynaptic Studies Using In Vivo Electro 
chemistry and Microdialysis. J. Pharm. Exp. Ther., 279:1 181 - 
1190 (1996); Hebert M. A. and Gerhardt, G. A., Behavioral 
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2 
and Neurochemical Effects of Intranigral GDNF Admini stra 
tion on Aged Fischer 344 Rats. J. Pharm. Exp. Ther., 282: 
760-768 (1997); Hou, J. G. G., et al., Glial Cell line-Derived 
Neurotrophic Factor Exerts Neurotrophic Effects on Dopam 
inergic Neurons In Vitro and Promotes Their Survival And 
Regrowth After Damage by 1-Methyl-4-Phenylpyridinium. 
J. Neurochem., 66:74-82 (1996); Kordower, J. H., et al., 
Clinicopathological Findings Following Intraventricular 
Glial-Derived Neurotrophic Factor Treatment in a Patient 
with Parkinson’s Disease. Ann Neurol., 46(3):419-424 
(1999); Kordower, J. H., et al., Neurodegeneration Prevented 
by Lentiviral Vector Delivery of GDNF in Primate Models of 
Parkinson’s Disease. Science, 290:767-773 (2000); Pal?, S., 
et al., Lentivirally Delivered Glial Cell Line-derived Neu 
rotrophic Factor Increases the Number of Striatal Dopamin 
ergic Neurons in Primate Models of Nigrostriatal Degenera 
tion. J. Neurosci., 22:4942-4954 (2002); Tomac, A., et al., 
Protection and Repair of the Ni gro striatal Dopaminergic Sys 
tem by GDNF In Vivo, Nature, 373:335-339 (1995)). How 
ever, initial clinical trials involving ventricular delivery of 
GDNF showed no statistically signi?cant differentiation of 
the placebo and active treatment groups (Nutt, J. G., et al., 
ICV GDNF Study Group. Implanted intracerebroventricular. 
Glial Cell Line-derived Neurotrophic Factor. Randomized, 
Double-Blind Trial of Glial Cell Line-Derived Neurotrophic 
Factor (GDNF) in PD, Neurology, 60: 69-73 (2003)), perhaps 
because insu?icient amounts of GDNF reached critical target 
sites from the CSF (Ai, Y., et al., Intraputamenal Infusion in 
Aging Rhesus Monkeys: Distribution and Dopaminergic 
Effects. J. Comp Neurol. 461: 250-26125 (2003); Kordower, 
J. H., et al., (2000)). 
Consequently, there continues to exist a long-felt need for 
effective methods for the treatment and prevention of PD in 
humans. Accordingly, it is an object of the present invention 
to provide methods of treating PD in humans comprising 
intraputaminal convection-enhanced infusion of GDNF. This 
and other such objectives will be readily apparent to the 
skilled artisan from this disclosure. 
SUMMARY OF THE INVENTION 
A ?rst aspect of the present invention concerns a method of 
treating Parkinson’s disease in a human comprising admin 
istering a pharmaceutical composition comprising a pharma 
ceutically effective dose of a glial cell line-derived neu 
rotrophic factor (GDNF) protein product to one or both 
putamen of a human PD patient in need thereof. The GDNF 
protein product includes, without limitation, a pharmaceuti 
cally effective dose of r-metHuGDNF (a dimeric protein hav 
ing an the amino acid sequence shown below in Table 1) or 
variants and/ or derivatives thereof. The invention is based on 
the surprising discovery that convection-enhanced infusion 
of r-metHuGDNF to one or both putamen of a PD patient by 
means of at least one implantable pump and one or more 
indwelling catheters results in dramatic anti-parkinsonian 
and anti-dyskinetic effects which are further associated with 
impressive re-innervation and/or restoration of dopamine 
stores in previously dopamine de?cient neurons in human 
patients af?icted with PD. 
The methods of the present invention are contemplated to 
restore neural cell function in a patient having Parkinson’s 
disease. Furthermore, the methods described herein are use 
ful in repairing neural pathways damaged by Parkinson’s 
disease in humans. Speci?cally, the methods described herein 
are capable of stimulating nerve regeneration, including re 
innervation of damaged human brain tissue by dopaminergic 
neurons. In a related aspectthere is provided a method of 
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increasing the function of dopaminergic neurons that com 
prises convection-enhanced infusion of a pharmaceutically 
effective dose of r-metHuGDNF to one or both putamen of a 
human patient in need thereof using at least one implantable 
pump and at least one catheter. 
The present invention also concerns the use of a pharma 
ceutically effective amount of GDNF and at least one phar 
maceutically acceptable vehicle, excipient, or diluent in the 
preparation of a pharmaceutical composition for increasing 
the function of dopaminergic neurons, wherein the composi 
tion is administeredto one or both putamen of a human in need 
thereof via convection-enhanced infusion using at least one 
implantable pump and at least one catheter. 
Additionally provided are methods of treating cognitive 
disorders in humans that comprise administeration of a phar 
maceutically effective dose of r-metHuGDNF to one or both 
putamen of a human patient in need thereof via convection 
enhanced infusion using at least one implantable pump and at 
least one catheter. 
Another aspect of the present invention includes methods 
of treating PD or cognitive disorders comprising the admin 
isteration of a pharmaceutically effective dose of r-metH 
uGDNF to one or both putamen of a human in need thereof 
via convection-enhanced infusion using at least one implant 
able pump and at least one catheter and assessing dopamin 
ergic function in the brain of said human pre-operatively, and, 
optionally, assessing dopaminergic function in the brain of 
said human periodically post-operatively. 
The methods disclosed herein may also provide a prophy 
lactic function in humans. More speci?cally, one embodi 
ment of the present invention includes a method of preventing 
PD in a human comprising administration of r-metHuGDNF 
to one or both putamen of a human via convection-enhanced 
infusion using at least one implantable pump and at least one 
catheter. Another embodiment of the present invention 
includes methods of preserving dopaminergic neural cell 
function in a human having, or at risk of having, a neurode 
generative disorder comprising administration of r-metH 
uGDNF to one or both putamen of a human via convection 
enhanced infusion using at least one implantable pump and at 
least one catheter. The neurodegenerative disorder may be 
Parkinson’s disease or multiple system atrophy (MSA). 
According to the invention, r-metHuGDNF administered via 
convection-enhanced infusion to the human putamen is con 
templated to preserve the integrity of the nigrostriatal path 
way in the human brain. Prophylactically administering 
GDNF via convection-enhanced infusion of r-metHuGDNF 
in accordance with the invention is contemplated as a method 
of preventing or treating degeneration of the nigrostriatal 
pathway or loss of functional dopaminergic activity associ 
ated with a neurodegenerative disorder. The neurodegenera 
tive disorder prevented or treated includes Parkinson’s dis 
ease and MSA. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1(a) and 1(b) illustrate the placement of multiport 
infusion catheters (represented by white circles except patient 
6, represented by a black circle for clarity). Images were 
normalized to the Talirach atlas in Analyze version 5.0, and 
the catheter locations mapped to a single axial slice level (+4 
mm). The target for multiport catheter placement was the 
mid-dorsal putamen. Numbers indexing each location repre 
sent the corresponding patient designation. The reference 
anatomic underlay is the Talairach-normalized average 
T1-weighted image with superimposed lenticular nucleus 
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map (dark greyiputamen; light grenglobus pallidus) from 
the ten subjects. LiPatient Left. Scale Bar (top right)—10 
mm. 
FIGS. 2(a) and 2(b) depicts patient assessments made 
using validated quality of life questionnaires: the 39-item 
Parkinson’s Disease Questionnaire (PDQ 39; FIG. 2(a)) and 
the 36-item Medical Outcomes Study short form health sur 
vey (SF-36; FIG. 2(b)) before surgery and after 3, 6, 12, 18, 
and 24 months of convection-enhanced infusion of r-metH 
uGDNF to the putamen, either unilaterally or bilaterally, 
using one or more single-port catheters. 
FIGS. 3(a) and 3(b) depicts the UPDRS scores for patients 
at 0, 3, 6, 12, 18, and 24 months of convection-enhanced 
infusion of r-metHuGDNF to the putamen, either unilaterally 
or bilaterally using one or more single-port catheters. 
DETAILED DESCRIPTION OF CERTAIN 
PREFERRED EMBODIMENTS 
This invention is based on the discovery that convection 
enhanced infusion of GDNF to one or both putamen of a 
human PD patient using at least one implantable pump and at 
least one indwelling catheter results in surprisingly dramatic 
anti-parkinsonian and anti-dyskinetic effects which are asso 
ciated with impressive re-innervation and restoration of 
dopamine stores in previously dopamine de?cient neurons. 
Macromolecules like GDNF diffuse slowly in brain paren 
chyma and usually over only short distances (Bobo, R. H., et 
al., Convection-Enhanced Delivery of Macromolecules in the 
Brain. Proc. Nat. Acad. Sci USA, 91:2076-2080 (1994)). 
Convection enhanced delivery (CED) to the brain uses bulk 
?ow in the extracellular space that results from a pressure 
gradient to signi?cantly enhance tissue penetration and dis 
tribute macromolecules over larger volumes in relatively 
homogenous concentrations and largely independent of 
molecular weight. This is in stark contrast to diffusion that is 
dependent on establishing a concentration gradient and 
depends heavily on molecular weight (Bobo, et al., (1994); 
US. Pat. Nos. 5,720,720, 6,093,802 and 6,184,200 (the US. 
patents are hereby incorporated by reference in their 
entirety); Chen, M. Y., et al., Variables Affecting Convection 
Enhanced Delivery to the Striatum: a Systematic Examina 
tion of Rate of Infusion, Cannula Size, Infusate Concentra 
tion, and Tissue-Cannula Sealing Time, J. Neurosurg., 
90:315-20 (1999); Hamilton, J. F., et al., Heparin Coinfusion 
During Convection-Enhanced Delivery (CED) Increases the 
Distribution of the Glial-Derived Neurotrophic Factor 
(GDNF) Ligand Family in Rat Striatum and Enhances the 
Pharmacological Activity of Neurturin, Exp. Neurol., 168: 
155-61 (2001); Nguyen, T. T., et al., Convective Distribution 
of Macromolecules in the Primate Brain Demonstrated Using 
Computerized Tomography and Magnetic Resonance Imag 
ing, J. Neurosurg., 98:584-90 (2003)). In a recent study in 
nonhuman primates (Gash, et al., unpublished data), GDNF 
was seen to have an average area of distribution of3118 mm2 
when delivered with a single port catheter (1 mm in diameter 
with a 0.25 mm diameter port at the tip; Medtronic model 
8770IP1A) and 119116 mm2 with a multiport catheter (1 mm 
in diameter with 24 ports, each 0.075 mm in diameter; 
Medtronic model 877OIP24A) using the same pump delivery 
parameters. This ?nding is consistent with other studies that 
show convection-enhanced infusion distributes large mol 
ecules far more extensively at a relatively homogenous con 
centration as compared to diffusion alone (Lieberman, D. M., 
et al., Convection-Enhanced Distribution of Large Molecules 
in Gray Matter During Interstitial Drug Infusion, J. Neuro 
surg., 82:1021-1029 (1995)). 
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One aspect of the present invention provides methods of 
treating or preventing neurodegenerative disorders in a 
human that comprise administering a pharmaceutical com 
position comprising a pharmaceutically effective amount of a 
GDNF protein product and at least one pharmaceutically 
acceptable vehicle, excipient, or diluent to one or both puta 
men of a human in need thereof via convection-enhanced 
infusion using at least one implantable pump and at least one 
catheter. The neurodegenerative disorder may be Parkinson’ s 
disease or MSA. 
In another embodiment of the present invention, in con 
junction with the above and below embodiments, at least one 
catheter is a multiport catheter. Additionally (or alterna 
tively), the infusion may be pulsed. 
In another embodiment of the present invention, in con 
junction with the above and below embodiments, at least one 
catheter may be a single-port catheter from about 1 mm in 
diameter to about 0.5 mm in diameter and wherein the port is 
at its distal end. Additionally (or alternatively), the infusion 
may be pulsed. 
Another embodiment of the present invention provides a 
method of treating Parkinson’ s disease in a human that com 
prises administering a pharmaceutical composition compris 
ing a pharmaceutically effective amount of a GDNF protein 
product and at least one pharmaceutically acceptable vehicle, 
excipient, or diluent to one or both putamen of a human in 
need thereof via convection-enhanced infusion of the phar 
maceutical composition using at least one implantable pump 
and at least one catheter with a single port at its distal end. 
Another embodiment of the present invention provides a 
method of treating Parkinson’ s disease in a human that com 
prises administering a pharmaceutical composition compris 
ing a pharmaceutically effective amount of a GDNF protein 
product and at least one pharmaceutically acceptable vehicle, 
excipient, or diluent to one or both putamen of a human in 
need thereof via convection-enhanced infusion of the phar 
maceutical composition using at least one implantable pump 
and at least one catheter with a single port at its distal end and 
wherein the infusion of the composition is pulsed. 
The methods of the present invention may comprise con 
tinuous and/ or pulsed delivery of GDNF through one or more 
catheters with a diameter of about 1 mm to about 0.5 mm and 
having a single port at its distal end to promote convection 
enhanced distribution of GDNF which allows local tissue 
concentrations of GDNF to reach threshold levels. In some 
embodiments of the invention, the method comprises con 
tinuous and/ or pulsed delivery of GDNF utiliZing one or more 
catheters with a diameter of about 0.8 mm to about 0.6 mm 
and having a single port at its distal end to promote convection 
enhanced distribution of GDNF which allows local tissue 
concentrations of GDNF to reach threshold levels. In other 
embodiments of the invention, the method comprises con 
tinuous and/ or pulsed delivery of GDNF utiliZing one or more 
catheters with a diameter of about 0.6 mm and having a single 
port at its distal end to promote convection enhanced distri 
bution of GDNF which allows local tissue concentrations of 
GDNF to reach threshold levels. 
Unilateral delivery of GDNF by a pulsed ?ow sequence 
administered contralaterally to the most affected side using a 
multi-port catheter resulted in motor improvement bilaterally 
comparable to improvement seen for bilateral putamenal 
GDNF continuous using a 0.6 mm diameter single port cath 
eter (Gill, et al., (2003)). With both approaches, the total 
UPDRS scores improved in OFF and ON after 6 months of 
GDNF treatment. Timed motor tests also improved, with 
improvements seen in both ON and OFF. Patients adminis 
tered GDNF contralaterally to the most affected side, did not 
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experience aphthous mouth ulcers and only two reported mild 
Lhennitte’s syndrome. Bilateral effects were observed in all 
ten subjects. These bilateral improvements associated with 
unilateral GDNF treatment as disclosed herein support a 
facilitatory effect of improved function in the ipsilateral puta 
men on bilateral motor pathways. Furthermore, the apparent 
bilateral effects from unilateral administration of GDNF are 
surprising and unexpected in that they are not consistent with 
the known dopaminergic circuitry of the basal ganglia, but are 
consistent with crossed glutamatergic projections from the 
motor cortex (Barbeito, L., et al., Activation of the Bilateral 
Corticostriatal Glutamatergic Projection by Infusion of 
GABA into Thalamic Motor Nuclei in the Cat: an In Vivo 
Release Study, Neuroscience, 28:365-374 (1989); Glowin 
ski, 1., et al., Role of the Thalamus in the Bilateral Regulation 
of Dopaminergic and GABAergic Neurons in the Basal Gan 
glia. Ciba Found Symp. 107:150-163 (1984)). 
Accordingly, effective methods of treating or preventing 
the pathological hallmarks of Parkinson’s disease in humans 
as well as the devastating symptoms of PD are provided by the 
present invention. 
The section headings used herein are for organizational 
purposes only and are not to be construed as limiting the 
subject matter described. 
Abbreviations 
In the preceding description and the experimental disclo 
sure which follows, the following abbreviations apply: 
6-OHDA 6-hydroxydopamine 
ALS amyotrophic lateral sclerosis 
ASA acute systemic anaphylaxis 
AUC area under the concentration vs time curve 
CAPIT Core Assessment Program for Intracerebral Trans 
plantations 
CAPS 3-(cyclohexylamino)-l-propanesulfonic acid 
CHO Chinese hamster ovary 
CI continuous infusion 
CSF cerebrospinal ?uid 
CT computed tomography 
DA dopamine, dopaminergic 
DOPAC 3,4-dih:ydroxyphenylacetic acid 
E. coli Escherichia coli 
FCA Freund’s Complete Adjuvant 
GDNF glial cell line-derived neurotrophic factor 
GLP Good Laboratory Practice 
HPLC high-performance liquid chromatography 
HVA homovanillic acid 
ICV intracerebroventricular 
IM intramuscular 
ISN intranigral 
IT intrathecal 
IV intravenous 
L-dopa 3,4-dihydroxyphenylalanine (levodopa) 
r-metHuGDNF recombinant-methionyl human GDNF 
MPTP 1 -methyl-4-phenyl- l ,2,3 ,6-tetrahydropyridine 
PD Parkinson’s disease 
PET positron-emission tomography 
pmn progressive motor neuropathy 
Ret receptor tyrosine kinase 
r-metHuGDNF recombinant-methionyl human GDNF 
SC subcutaneous 
SDS-PAGE sodium dodecylsulfate-polyacrylamide gel 
electrophoresis 
SEM standard error of the mean 
TGF transforming growth factor 
TH tyrosine hydroxylase 
TH+ tyrosine hydroxylase positive 
UPDRS Uni?ed Parkinson’s Disease Rating Scale 
US 8,946,152 B2 
7 
De?nitions 
Unless otherwise noted, technical terms are used according 
to conventional usage. As utilized in accordance with the 
present disclosure, the following terms shall be understood to 
have the following meanings: 
As used herein, the term “catheter” refers to any tubular 
medical device for insertion-into a cavity, tissue, organ, or any 
substructure thereof of a living mammal to permit injection of 
a therapeutic agent. As particularly used here, a catheter is 
used to deliver r-metHuGDNF to the brain or substructures 
thereof such as the putamen. An “indwelling” catheter is one 
that is implanted and left in place for protracted periods, such 
as ?fteen minutes or longer. 
As used herein, the phrase “catheter system” refers to the 
combination of at least one catheter and at least one accessory 
device including, but not limited to, an anchor, stylet, guide 
tube, guide wire or a combination thereof. 
“Continuous delivery” or “chronic infusion” are inter 
changeable and are intended to mean delivery of a substance 
over a period of time such that the procedure is distinguished 
from “bolus” delivery. Continuous delivery generally 
involves the delivery of a substance over a period of time 
without interruption. The rate of delivery need not be con 
stant, and may be pulsed, and the period of delivery need not 
be very long, i.e., the period of constant delivery may be over 
a period of maybe half an hour or an hour or a few hours, but 
may also be over a period of days, weeks, months, or even 
years. A pulse consists of periodic increases in the ?ow rate 
for intervals ranging from seconds to minutes, to hours, 
which, as used herein, enchances convection enhanced deliv 
ery of the drug into brain tissue. 
“Admixing” as used herein denotes the addition of an 
excipient to a polypeptide of interest, such as by mixing of dry 
reagents or mixing of a dry reagent with a reagent in solution 
or suspension, or mixing of aqueous formulations of reagents. 
“Excipient” as used herein denotes a non-therapeutic agent 
added to a pharmaceutical composition to provide a desired 
consistency or stabilizing effect. 
“Implanted” means placed within the body, and main 
tained at that location for some extended period of time. As 
used herein it is intended that the period of time during which 
the implanted object is maintained in place will be, in general, 
considerably greater than that customarily required to intro 
duce a bolus of a substance, such as a drug. For example, a 
catheter used in a method of the invention may be placed 
within a tissue or organ such that the catheter so implanted is 
intended to remain at the site of implantation for some 
extended period of time. Some of the drug delivery appara 
tuses that may be used in the methods of the invention, for 
example the drug pumps and/or catheters, are designed to be 
implanted for periods greater than a month and even years and 
to deliver drug during this period. A drug delivery apparatus 
may be implanted, for example, subcutaneously, or within a 
tissue or organ, or within a body cavity such as the peritoneal 
cavity, infraclavicular space, the thoracic cavity, the pelvic 
cavity, or any other cavity or location that is convenient for 
delivery of the intended substance. A catheter may be 
implanted into a tissue, for example into brain tissue, and may 
be af?xed in place by ?xing the catheter to another tissue, 
such as bone, e.g., the skull, or cartilage, using an adhesive or 
screws, clamps, sutures or any other suitable ?xing means. 
The phrases “dopaminergic dysfunction”, “dopaminergic 
dysregulation”, “dopaminergic degeneration”, “dopamine 
depleted”, “dopamine de?cient”, or grammatical equivalents 
thereof, may be used interchangeably herein. All such phrases 
are intended to encompass at least one of the following con 
ditions or disorders: Parkinson’s disease, neuronal dopamine 
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de?cit, dopaminergic neuron de?cit, dopaminergic neuron 
lesions, hypo-dopaminergic innervation, dopamine synthesis 
incapacity, dopamine storage incapacity, dopamine transport 
incapacity, or dopamine uptake incapacity. Dopaminergic 
dysfunction can be evidenced by analyzing factors including, 
but not limited to, the following: 1) the number of TH express 
ing neurons 2) size of dopamine neuronal cells 3) dopamine 
metabolite levels 4) dopamine uptake, 5) dopamine transport, 
6) neuronal dopamine uptake, 7) dopamine transporter bind 
ing, 8) quantal size of terminal dopamine release, 9) rate of 
dopamine turnover, 10) TH+ cell count, 11) TH+ innervation 
density and 12) TH+ ?ber density. 
The phrase “target site”, or a grammatical version thereof, 
refers to the site for intended delivery of a substance, such as 
a drug. In particular embodiments of the present invention, a 
preferred target site is an area of dopaminergic degeneration 
or dopaminergic dysfunction within the brain of a human 
a?licted with Parkinson’ s disease. More preferably, the target 
site includes one or more site in the substantia nigra, globus 
pallidus, caudate nucleus, and putamen. Even more prefer 
ably, the target site includes the central area of the putamen. 
Even more preferably, the target site includesthe posterior 
area of the putamen. Mo st preferably, the target site includes 
the postero-dorsal area of the putamen. Furthermore, a par 
ticular target site may be targeted unilaterally or bilaterally 
with respect to the hemispheres of the brain. 
“Proximal end” is a relative term, and generally refers to 
the end of a device, such as a catheter that is nearest to the 
operator (i.e., the surgeon) and is furthest away from the 
treatment site. In the present invention a catheter has a proxi 
mal end that may be communicably attached to an access port 
or drug delivery apparatus, such as a pump, or reservoir. 
“Tyrosine hydroxylase-positive” or “TH+” is intended to 
refer to the presence of tyrosine hydroxylase in a referenced 
nervous tissue as indicated by the results from any technique 
known in the art as a means to detect and/or measure tyrosine 
hydroxyl ase, tyrosine hydroxylase encoding mRNA, or 
tyrosine hydroxylase activity. 
“Distal end” is a relative term and generally refers to the 
end of a device, such as a catheter, that is furthest away from 
the operator (i.e., the surgeon) and is closest to the treatment 
site. In the present invention the distal end of a catheter may 
be communicably attached to an opening that allows for the 
delivery of drug to the target site. 
“Drug delivery apparatus” as used herein includes but is 
not limited to, a drug reservoir and/or a drug pump of any 
kind, for example an osmotic pump, an electromechanicl 
pump, an electroosmotic pump, an effervescent pump, a 
hydraulic pump, a piezoelectric pump, an elastomeric pump, 
a vapor pressure pump, or an electrolytic pump. Preferably, 
such a pump is implanted within the body. 
Throughout this speci?cation, reference to the term 
“GDNF” or the phrase “GDNF protein product” or “GDNF 
polypeptide”, all of which are used interchangeably, refers to 
glial cell line-derived neurotrophic factor from any species, 
including murine, bovine, ovine, porcine, equine, avian, and 
preferably human, in native sequence or in genetically engi 
neered variant form, including, without limitation, biologi 
cally active fragments, analogs, variants, (including, inser 
tion, substitution, and deletion variants) and derivatives 
thereof, and from any source, whether natural, synthetic, or 
recombinantly produced. 
Exemplary GDNF polypeptides useful in the present 
invention include, without limitation, any of GDNF protein 
products described in Us. Pat. Nos. 5,731,284, 6,362,319, 
6,093,802, and 6,184,200 (all of which are hereby incorpo 
rated by reference in their entireties). Preferred GDNF pro 
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include, but are not limited to, r-metHuGDNF, a recombinant 
GDNF protein produced in E coli which has an amino acid 
sequence identical to native mature human GDNF with the 
addition of an amino terminal methionine. Thus, r-metH 
uGDNF consists of 135 amino acids. Seven of the amino 
acids are cysteines, which are involved in one intermolecular 
disul?de bond and three intramolecular disul?de bonds. In its 
active form, r-metHuGDNF is a disul?de-bonded 
homodimer. The primary amino acid sequence of monomeric 
r-metHuGDNF (SEQ ID NO: 1) is provided in Table 1. 
TABLE 1 
Amino 
Ac id 
Primary Amino Acid Sequence No . 
HZN—Met Ser Pro Asp Lys Gln Met Ala Val Leu Pro 10 
Arg Arg GluArg Asn Arg GlnAla Ala Ala 20 
AlaAsn Pro Glu Asn SerArg Gly Lys Gly 30 
Arg Arg GlyGln Arg Gly Lys Asn Arg Gly 40 
Cys Val Leu Thr Ala Ile His LeuAanal 50 
Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys 6 O 
Glu Glu Leu I le Phe Arg Tyr Cys Ser Gly 70 
Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp 8O 
Lys Ile Leu Lys Asn LeuSer Arg Asn Arg 90 
Arg Leu Val Ser Asp Lys Val Gly GlnAla lOO 
Cys Cys Arg Pro Ile Ala PheAsp Asp Asp 110 
Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr 120 
His Ile LeuArg Lys His SerAla Lys Arg 130 
Cys Gly Cys I le COOH 134 
The GDNF protein products useful in the present invention 
may be isolated or generated by any means known to those 
skilled in the art. Preferably, GDNF is recombinantly pro 
duced. In a preferred method, the GDNF is cloned and its 
DNA expressed, e.g., in mammalian cells or bacterial cells. 
Exemplary methods for producing GDNF protein products 
useful in the present invention are described in US. Pat. Nos. 
6,362,319, 6,093,802 and 6,184,200 (all ofwhich are hereby 
incorporated by reference in their entireties). 
GDNF pharmaceutical compositions typically comprise a 
therapeutically effective amount of at least one GDNF protein 
product and one or more pharmaceutically and physiologi 
cally acceptable formulation agents. Suitable formulation 
agents include, but are not limited to, antioxidants, preserva 
tives, coloring, ?avoring and diluting agents, emulsifying 
agents, suspending agents, solvents, ?llers, bulking agents, 
buffers, vehicles, diluents, excipients and/or pharmaceutical 
adjuvants. For example, a suitable vehicle may be, physi 
ological saline solution, citrate buffered saline, or arti?cial 
CSF, possibly supplemented with other materials common in 
compositions for parenteral administration. Neutral buffered 
saline or saline mixed with serum albumin are further exem 
plary vehicles. Those skilled in the art would readily recog 
nize a variety of buffers that could be used in the composi 
tions, and dosage forms used in the invention. Typical buffers 
include, but are not limited to pharmaceutically acceptable 
weak acids, weak bases, or mixtures thereof. Preferably, the 
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buffer components are water soluble materials such as phos 
phoric acid, tartaric acids, lactic acid, succinic acid, citric 
acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, 
and salts thereof. 
The primary solvent in a vehicle may be either aqueous or 
non-aqueous in nature. In addition, the vehicle may contain 
other pharmaceutically-acceptable excipients for modifying 
or maintaining the pH, osmolarity, viscosity, clarity, color, 
sterility, stability, rate of dissolution, or odor of the formula 
tion. A preferred pharmaceutical composition of GDNF com 
prises a therapeutically effective amount of at least one 
GDNF protein and a pharmaceutically acceptable vehicle. 
More preferably, the pharmaceutically acceptable vehicle is 
an aqueous buffer. More preferably, the vehicle comprises 
sodium chloride at a concentration of about 100 mM to about 
200 mM and sodium citrate at a concentration of about 5 mM 
to about 20 mM. Even more preferably, the vehicle comprises 
sodium chloride at a concentration of about 125 mM to about 
175 mM and sodium citrate at a concentration of about 7.5 
mM to about 15 mM. Even more preferably, the vehicle 
comprises sodium chloride and sodium citrate at a concen 
tration of about 150 mM and about 10 mM, respectively. Most 
preferably, the GDNF pharmaceutical composition is formu 
lated as a liquid with 10 mM sodium citrate and 150 mM 
sodium chloride at a pH of5.0. 
The GDNF pharmaceutical composition may contain still 
other pharmaceutically-acceptable formulation agents for 
modifying or maintaining the rate of release of GDNF protein 
product. Such formulation agents are those substances known 
to artisans skilled in formulating sustained release formula 
tions. For further reference pertaining to pharmaceutically 
and physiologically acceptable formulation agents, see, for 
example, Remington’s Pharmaceutical Sciences, 18th Ed. 
(1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435 
1712 (the disclosure of which is hereby incorporated by ref 
erence). 
Once the therapeutic composition has been formulated, it 
may be stored in sterile vials as a solution, suspension, gel, 
emulsion, solid, or dehydrated or lyophilized powder. Such 
formulations may be stored either in a ready to use form, a 
lyophilized form requiring reconstitution prior to use, or a 
liquid form requiring dilution prior to use. Preferably, the 
GDNF pharmaceutical composition is provided in sterile 
single-use vials at a concentration of 10 mg/mL and stored at 
a temperature of —2-80 C. until use. Immediately prior to 
administration, the GDNF protein product should be thawed 
and appropriately diluted with a sterile citrate buffered saline 
(pH 5.0) consisting of 150 mM sodium chloride and 10 mM 
sodium citrate. 
In the methods of the present invention, GDNF is chroni 
cally administered to a site of dopaminergic dysfunction in 
the human brain by means of an implantable pump and one or 
more catheters. The region of a PD patient’ s brain targeted for 
chronic delivery of GDNF may be determined by assessing 
biomarkers of PD disease or disease progression including, 
but not limited to, the number of TH expressing neurons 2) 
size of dopamine neuronal cells 3) dopamine metabolite lev 
els 4) dopamine storage, 5) dopamine transport, 6) neuronal 
dopamine uptake, 7) dopamine transporter binding, 8) quan 
tal size of terminal dopamine release, 9) rate of dopamine 
turnover, 10) TH+ cell count, 11) TH+ innervation density 
and 12) TH+ ?ber density. For instance, GDNF may be 
infused directly into a region of the human brain which is 
severely dopamine depleted. The region of a PD patients 
brain which is severly dopamine depleted and, therefore, a 
target for chronic delivery of GDNF may be determined by 
neuroimagery of the brain, or regions thereof. The neuroim 
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agery technique used to determine the site of chronic infusion 
of GDNF may be selected from the group consisting of 18F 
?uorodopa positron emission tomography (1 8F-dopa PET) 13, 
l 23 1-26 -carboxymethoxy-3 [3 -(4-iodophenyl)tropane uptake 
on single-photon emission tomography (123I-[3-CIT SPECT), 
and similar techniques. In a preferred embodiment of the 
present invention, GDNF is infused directly into at least one 
dopaminergic dysfunctional putamen of a PD patient. Even 
more preferably, GDNF is infused directly into the posterior 
region of at least one dopaminergic dysfunctional putarnen of 
a PD patient. Mo st preferably, GDNF is infused directly into 
at least one dopaminergic dysfunctional postero-dorsal puta 
men of a PD patient. 
A number of drug delivery apparatus, catheters, catheter 
systems and combinations thereof have been developed for 
the dispensing of medical substances to speci?c sites within 
the body and are all readily available to those skilled in the art 
for use in the methods of the present invention. Therefore, one 
may use prior art drug delivery devices, catheters, and cath 
eter systems for delivering the GDNF compositions to the 
target site of the brain of the patient at speci?ed concentra 
tions and/or at speci?ed times and/or at different delivery 
rates. By way of illustration and not limitation, in the methods 
of the present invention one may use the technology 
described in Us. Patent Publication No. US20030120262, 
US20030208184, or US20030225372 or U.S. Pat. Nos. 
4,931,050, 4,838,887, 5,207,666, 4,714,462; 5176,641; 
3,923,060, 4,003,379, 4,588,394, 4,447,224, 5,575,770, 
4,978,338, 5,908,414, 5,643,207, 6,589,205 or 6,592,571. 
The entire disclosure of each of these U.S. Patent Applica 
tions and Us. Patents is hereby incorporated by reference 
into this speci?cation. A preferred drug delivery apparatus 
useful in the context of the present invention includes one 
described in Us. Pat. No. 5,752,930 or U.S. patent applica 
tion No. US20030216714 (which are hereby incorporated by 
reference in their entireties). A more preferred drug delivery 
apparatus useful in the context of the present invention 
includes one described in Us. Pat. No. 6,620,151 (which is 
hereby incorporated by reference in its entirety). An even 
more preferred drug delivery apparatus useful in the context 
of the present invention includes one described in Us. patent 
application No. US20030216714 (which is hereby incorpo 
rated by reference in its entirety). Most preferably the drug 
delivery apparatus used in the context of the present invention 
is one described in Us. Pat. Nos. 4,146,029, 4,013,074, or 
4,692,147, (which are hereby incorporated by reference in 
their entireties) commercial embodiments thereof including, 
but not limited to, the Synchromed® I, Synchromed® EL, 
and Synchromed® II infusion pumps (Medtronic, Inc., Min 
neapolis, Minn). 
In another embodiment of the present invention, in con 
junction with any of the above or below embodiments, a 
number of catheters and catheter systems have been devel 
oped for the dispensing of agents, such as drugs, to speci?c 
sites in the body and are readily available to those skilled in 
the art for use in the methods of the present invention. By way 
of illustration and not limitation, in the methods of the present 
invention one may use the technology described in Us. 
Patent Publication No. 20030216700, 20030199831, or 
20030199829 or U.S. Pat. No. 6,319,241. The entire disclo 
sure of these U.S. patent applications and the United States 
patent is hereby incorporated by reference into this speci? 
cation. 
The methods of the present invention are also achievable 
by infusion of GDNF utiliZing a single port catheter. A single 
port catheter is a catheter having one hole or port, generally 
disposed at the distal end of the catheter. Accordingly, a 
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catheter or catheter system useful in the context of the present 
invention includes, but is not limited to, an intraparenchym al 
infusion catheter or catheter system described in International 
Patent Application Publication No: WO 02/07810, WOO3/ 
002170, or WO 03/077785, or U.S. Pat. Nos. 5,720,720, 
6,551,290, 6,093,180 or 6,609,020. The entire disclosure of 
each of these Patent Applications and United States patents is 
hereby incorporated by reference into this speci?cation. 
The methods of the present invention are also achievable 
by infusion of GDNF utiliZing a multiport catheter. A multi 
port catheter is a catheter having a plurality of infusion holes 
or ports disposed along the length of the catheter or catheter 
tip. Generally, a multiport catheter will have said infusion 
holes or ports longitudinally spaced along the tip length at 
substantially regular intervals. A multiport catheter therefore 
may have about 20 to about 60 ports, about 30 to about 50 
ports, or about 35 to about 45 ports, along its length or the 
length of the catheter tip. A catheter useful in the methods of 
the present invention includes, but is not limited to, an intra 
putamenal (IPA) multiport catheter having 40 ports arranged 
4 per 0.5 mm placed approximately every 90°, about 5 mm 
length, such as model #10532, manufactured by Medtronic, 
Inc. (Minneapolis, Minn.), or any catheter substantially simi 
lar thereto. 
In another embodiment of the methods of the present 
invention, in conjunction with any of the above or below 
embodiments, a therapeutically effective dose of GDNF is 
infused directly into one or both putamen of a human PD 
patient. The phrase “therapeutically effective dose” or “phar 
maceutically effective dose”, which are used interchangeably 
herein, refers to that amount of GDNF suf?cient to result in 
any amelioration, impediment, prevention or alteration of any 
biological symptom generally associated with a neurodegen 
erative disorder including, without limitation, PD by one 
skilled in the relevant art. In a preferred embodiment of the 
present invention, in conjunction with any of the above or 
below embodiments, GDNF is directly into a human putamen 
at a dose of about 1 ug/putamen/day to about 100 ug/putamen/ 
day. More preferably, GDNF is infused directly into a human 
putamen at a dose of about 5 ug/putamen/day to about 50 
ug/putamen/day. Even more preferably, GDNF is infused 
directly into a human putamen at a dose of about 10 ug/puta 
men/ day to about 75 ug/putamen/ day. Even more preferably, 
GDNF is infused directly into a human putamen at a dose of 
about 15 ug/putamen/day to about 50 ug/putamen/ day. Even 
more preferably, r-metHuGDNF is infused directly into a 
human putamen at a dose of about 20 ug/putamen/day to 
about 45 ug/putamen/ day. Even more preferably, r-metH 
uGDNF is infused directly into a human putamen at a dose of 
about 25 ug/putamen/day to about 40 ug/putamen/ day. Even 
more preferably, r-metHuGDNF is infused directly into a 
human putamen at a dose of about 30 ug/putamen/day to 
about 35 ug/putamen/ day. Mo st preferably, r-metHuGDNF is 
infused directly into a human putamen at a dose of about 30 
ug/putamen/day. 
Applicants also disclose herein the use of a pharmaceuti 
cally effective amount of GDNF including, but not limited to, 
r-metHuGDNF, and at least one pharmaceutically acceptable 
vehicle, excipient, or diluent in the preparation of a pharma 
ceutical composition for treating cognitive disorders or inhib 
iting cognitive decline associated with neurodegenerative 
disorders, including, without limitation, PD and dementia, 
wherein the composition is for administration to one or both 
putamen of a human in need thereof via convection-enhanced 
infusion using at least one implantable pump and at least one 
catheter. In a preferred use of a pharmaceutically effective 
amount of GDNF and at least one pharmaceutically accept 
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able vehicle, excipient, or diluent in the preparation of a 
pharmaceutical composition for treating cognitive disorders 
or inhibiting cognitive decline associated with neurodegen 
erative disorders, including, without limitation, PD and 
dementia, the composition is for administration to a site of 
dopaminergic dysfunction within one or both putamen of a 
human in need thereof via convection-enhanced infusion 
using at least one implantable pump and at least one catheter. 
For such uses dopaminergic dysfunction is pre-operatively. In 
another embodiment of the present invention, in conjunction 
with any of the above or below embodiments 
The inventive method has the effect, upon application to 
parkinsonian patients, of signi?cantly reducing symptoms of 
Parkinson’s disease, the resulting improved condition of the 
patient continuing for at least 30 months. In particular, a clear 
improvement of disease-speci?c symptoms was obtained 
with the inventive method insofar as motoricity, ?ne motor 
icity, and ?ne dexterity. In addition, mobility and concentra 
tion power was increased and reaction time was decreased. 
Pronunciation, facial expressiveness, posture, sense of smell, 
libido, sexual function, and emotional condition were 
improved and state of mind was brightened. 
In yet another embodiment of the present invention, GDNF 
can be used as a cognitive enhancer, to enhance learning, 
particularly as a result of dementias or trauma, or to inhibit 
cognitive decline and/or dementia, for example, in patients 
with PD. Alzheimer’s disease, which has been identi?ed by 
the National Institutes of Aging as accounting for more than 
50% of dementia in the elderly, is also the fourth or ?fth 
leading cause of death in Americans over 65 years of age. 
Four million Americans, 40% of Americans over age 85 (the 
fastest growing segment of the US. population), have Athe 
imer’s disease. Twenty-?ve percent of all patients with Par 
kinson’s disease also suffer from Atheimer’s disease-like 
dementia. Applicants have shown here for the ?rst time that 
chronic intraputaminal administration of GDNF has applica 
tion in treating or preventing cognitive disorders in humans. 
In particular, intraputaminal administration of GDNF has 
application in treating or preventing cognitive disorders and/ 
or Alzheimer’s disease-like dementia associated with PD. 
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EXAMPLES 
The following examples, including the experiments con 
ducted and results achieved are provided for illustrative pur 
poses only and are not to be construed as limiting the inven 
tion. 
Example 1 
Unilateral Intraputamenal GDNF Improves Bilateral 
Motor Functions in Patients with Parkinson’s 
Disease 
Methods 
Subjects 
Consent from the patients described in Example 1 was 
obtained in accordance with the FDA and the local University 
of Kentucky Medical Center Internal Review Board regula 
tions and guidelines. Patients were diagnosed with idiopathic 
PD according to standard criteria (Hughes, A. 1., et al., What 
features improve the accuracy of clinical diagnosis in Parkin 
son’s disease: A clinicopathologic study?, Neurology, 
42: 1 142-1 146 (1992)). Eightmen and two women, aged 47 to 
70 years (see Table 2), with moderate to severe idiopathic PD 
(Hoehn and Yahr Stage 3-4) were selected for the study. 
Primary symptoms were rigidity and bradykinesia with dis 
ease duration ranging from 4.8 to 15.4 years (Table 2). Exclu 
sion criteria included the presence of clinically signi?cant 
depression or dementia, concomitant disease likely to inter 
fere with the study, prior surgery for PD, drug or alcohol 
dependence/abuse, and inability or unwillingness to comply 
with long-term follow-up. Premenopausal subjects had to 
agree to abstinence or use of barrier methods of birth control 
during the study unless surgically sterile. No patients had had 
prior exposure to neuroleptics or used selegiline for two 
months prior to implantation of the catheter. For the two 
months prior to the study patients had had stable symptoms 
and had been maintained on a constant regimen of anti-PD 
medications consisting of L-dopa and/ or a dopamine agonist 
(range 300-2500 mg/day levodopa equivalents, see Nutt, J. 
G., et al., (2003)); a catechol-o-methyltransferase inhibitor 
(COMT) had been used by two subjects and amantadine by 
two patients. No changes were made inpatients’ anti-PD drug 
regimens during the course of the study. 
TABLE 2 
Patient Data, Side-Effects, and Other Effects of GDNF 
Patient # 
Age (years) 
Duration of disease (years) 
L—Dopa equivalents/day 
Change in medications after 6 mo. 
Taste Abnormalities 
Lherrnitte’s 
Hyponatraerrnia 
Improved Bladder Control 
Recovery of Sexual Function 
Improvement in Taste/ Smell 
Reduction in Hypomimia *(Off)* 
Reduced Hypophonia (Off and On)* + + + 
Improved Postural Stability (Off)* + + + + 
Decreased End—of—Dose Fluctuations* + + 
+ + +++++ 
Decreased Dyskinesia* + 
DELIVERY SYSTEM EFFECTS 
Headaches 
MRI Changes + + + + + 
Pump Related Discomfort + + + + + 
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Patient Data, Side-Effects, and Other Effects of GDNF 
Patient # 6 7 8 9 10 
Age (years) 50 63 69 68 47 
Duration of disease (years) 4.8 6.2 12.2 11.8 6.8 
L—Dopa equivalents/day 700 1775 1200 2500 500 
Change in medications after 6 mo. 
Taste Abnormalities + 
Lhermitte’s + 
Hyponatraemia 
Improved Bladder Control 
Recovery of Sexual Function 
Improvement in Taste/ Smell 
Reduction in Hypomimia *(Off)* + + + + + 
Reduced Hypophonia (Off and On)* + + 
Improved Postural Stability (Off)* + + + 
Decreased End—of—Dose Fluctuations* + + + + 
Decreased Dyskinesia* + + 
DELIVERY SYSTEM EFFECTS 
Headaches + + + + + 
MRI Changes + + + + + 
Pump Related Discomfort + + + + + 
Duration of disease is from onset ofsymptoms to week prior to surgery. L-Dopa Equivalents based on Nutt, .I. 
G., et al., (2003). Reduction in hypomimia (question 19, section 3 UPDRS). Reduced hypophonia (question 5, 
section 2 and question 18, section 3 UPDRS). Improved postural stability (questions 29 & 30, section 3 
UPDRS). Decreased end of dose ?uctuations (questions 36-39, section 4 UPDRS). Decreased dyskinesia 
(questions 32-34, section 4 UPDRS). 
Surgical Procedures 
Each patient had an MRI-based stereotactic implantation 
of an intraputamenal (IPA) multi-port catheter (1 .65 mm O.D. 
diameter, 40 holes, 4 per 0.5 mm placed every 90°, 5 mm 
length; Medtronic, Inc., Model #10532) and SynchroMed® 
pump (Medtronic, Inc., Model #8626L-18) contralateral to 
the most affected side (see FIG. 1(a) and FIG. 1(b)). For each 
patient, a Leksell headframe was applied and a 1 mm slice 
MRI scan was performed. Targeting of the catheter placement 
was achieved using the Leksell Surgi Plan® (Copyright© 
1991 -2003 Elekta Instruments AB Stockholm, Sweden). Fol 
lowing standard stereotactic surgical procedures, the IPA 
catheter was inserted into the medial putamen. The citrate 
buffered saline-primed infusion pump was implanted subcu 
taneously in the ipsilateral lower quadrant abdominal wall 
and a catheter was tunneled to connect the pump to the ind 
welling IPA catheter. Locations of all catheters are schemati 
cally shown in FIG. 1(a). A schematic of the infusion system 
is seen in FIG. 1B. A postoperative MRI and posterior-ante 
rior and lateral x-rays of the skull, chest and abdomen were 
performed 24 hours after surgery to con?rm placement of the 
catheter tip, continuity of the connections, and to detect puta 
menal hemorrhage. All catheters were seen to be within the 
putamen (see FIG. 1a). 
GDNF Treatment 
The recombinant-methionyl human glial cell line-derived 
neurotrophic factor (r-metHuGDNF) was prepared by 
Amgen, Inc. (Thousand Oaks, Calif.). The r-metHuGDNF 
was stored in single-use vials in a buffer of 10 mM citrate and 
150 mM sodium chloride (CBS) at pH 5.0. At implantation, 
the pump was ?lled with preservative-free CBS and pro 
grammed to infuse at 133 uL/day and pump re?lls occurred 
monthly. The pump was programmed to infuse at a continu 
ous basal infusion rate of 2 ul/hour. Small bolus injections 
(21.3 ul delivered in 117 seconds) were delivered every 6 
hours to supplement the basal rate and to increase the brain 
area affected by the drug. At the end of week four post sur 
gery, r-metHuGDNF infusion began, with dose escalations at 
eight week intervals from 3 ug/day to 10 ug/day to 30 ug/day. 
Solution concentrations of GDNF were adjusted to deliver the 
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same amount of ?uid (133 pl) per day. After 24 weeks of 
infusion, the remaining r-metHuGDNF was removed from 
the pump and the pump was ?lled with CBS. Due to the slow 
drug infusion rate, and the length of catheter tubing between 
the pump and the tip of the putamenal catheter, it takes 
approximately one week for r-metHuGDNF in the tubing to 
clear. Therefore, a total washout period of ?ve weeks was 
needed to assess the effects of four weeks of trophic factor 
withdrawal. After the drug washout, patients had the option of 
reinstating GDNF treatment at the highest previous tolerated 
dose level for an extended period. All ten subjects requested 
continuation of the GDNF infusions. 
Clinical Testing and Follow Up 
Clinical evaluations were based on 1) UPDRS Total ON 
and OFF Scores, 2) UPDRS Motor ON and OFF Scores and 
3) the Clinical Assessment Program for Surgical Interven 
tional Therapies in Parkinson’s Disease CAPSIT-PD (Defer, 
G-L., Core assessment program for surgical interventional 
therapies in Parkinson’s disease (CAPSIT-PD). Mov Dis., 
14:572-584 (1999)). All patients were evaluated using total 
UPDRS and CAPSIT-PD timed motor tests, and were 
requested to keep a personal diary. Required visits were 
scheduled weekly during the ?rst fourweeks of the study after 
pump implant. Thereafter, visits were scheduled monthly 
through the 24 weeks of GDNF therapy with a ?nal follow-up 
visit to assess the effects of GDNF washout. 
Statistical Methods 
For the UPDRS endpoints, comparison of mean responses 
across time was based on a linear mixed model with post hoc 
comparison of means based on Fisher’s protected least sig 
ni?cant differences procedure. Con?dence intervals for the 
percent change from baseline to the 24 week follow-up were 
obtained by the delta method and are based on a t-distribution 
with 9 degrees of freedom. For the CAPSIT-PD endpoints 
some patients could not complete some tasks in which case a 
score of 90 seconds was assigned to the Stand-Walk-Sit task 
and 30 seconds was assigned to the Hand-Arm movement 
test. Comparison of the distribution of responses was based 
on Friedman’s chi-square statistic with post hoc comparison 
of means based on Fisher’s protected least signi?cant differ 
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ences procedure applied to the ranks across time determined 
on a patient by patient basis. Control of the Type I error rate 
for testing each week of follow-up to the baseline week was 
obtained by applying the Bonferroni-Holm procedure (Holm, 
S. A simple sequentially rejective multiple test procedure. 
Scand. J. Statistics, 6: 65-70 (1979)). Statistical signi?cance 
was determined at the 0.05 level. 
Results 
Testing was conducted in an operationally-de?ned OFF 
condition: (i) anti-PD medications withheld for 2.5 times the 
duration of each drug’ s predicted serum half life, and (ii) prior 
to the subject’s ?rst dose of medication on the day of testing. 
Total UPDRS scores were signi?cantly improved by 16, 20 
and 33% in the OFF condition at 8, 16, and 24 weeks, respec 
tively (Table 3). Total UPDRS scores in the ON condition 
were also improved by 26, 23, and 34% at 8, 16, and 24 weeks 
post-GDNF, respectively. ON testing was performed within 
18 
out. In addition, eight patients showed improved postural 
stability in OFF, seven reported decreased end-of-dose ?uc 
tuations and three experienced decreased dyskinesia (Table 
2). Other motor/ sensory improvements included reduced 
hypophonia (OFF and ON) in six patients, reduced hypo 
mimia in eight patients and improved taste and smell reported 
by one patient (Table 2). The observed reduction in bradyki 
nesia was supported by the CAPSIT-PID measures of timed 
Hand-Arm and SWS tests. The results of testing in the OFF 
and ON condition are seen in Table 3. Bilateral axial move 
ments including balance and gait were measured in SWS 
testing and were improved by 26% in OFF at six months 
post-GDNF. Bilateral improvements were also evident in the 
Arm-Hand test measuring movement speed between two 
points 30 cm apart. Performance times of the Arm-Hand test 
were signi?cantly faster in both ON and OFF on both the 
contralateral and ipsilateral sides to 
TABLE 3 
GDNF Improves UPDRS and CAPSIT Measures 
8 WEEKS 
Tests BASELINE P* 3 rig/day P+ 
Total OFF 64 r 5 <.0001 54 r 4 (—16%) 0.011 
UPDRS ON 47 r 3 0.0005 35 r 3 (—26%) 0.0011 
Motor OFF 40 r 4 0.0004 35 r 3 (—13%) 0.029 
UPDRS ON 23 r 2 0.0201 15 r 3 (—35%) 0.0075 
CAPSIT OFF 39 r 8 0.0464 37 r 10 (—5%) 0.1741 
Stand,Wa1k, Sit ON 22 r 5 0.1032 19 r 3 (—14%) i 
CAPSIT OFF 18 r 2 0.0002 15 r 3 (—17%) 0.0792 
Contralateral ON 13 r 2 0.0004 12 r 2 (—8%) 0.2680 
Hand/Arm 
CAPSIT OFF 15 r 2 0.0005 12 r 1 (—20%) 0.0348 
Ipsilateral ON 12 r 2 0.0005 10 r 1 (—17%) 0.0242 
Hand/Arm 
16 WEEKS 24 WEEKS 
Tests 10 pg/day P++ 30 pg/day P+++ WASHOUT P++++ 
Total OFF 51 r 4 (—20%) 0.0014 43 r 5 (—33%) 0.0001 53 r 4 (—19%) 0.0037 
UPDRS ON 36 r 5 (—23%) 0.023 31 r 4 (—34%) <0.0001 34 r 4 (—30%) 0.0004 
Motor OFF 32 r 3 (—20%) 0.0034 28 r 4 (—30%) <0.0001 33 r 3 (—18%) 0.0038 
UPDRS ON 16 r 4 (—30%) 0.0166 16 r 4 (—30%) 0.0090 14 r 3 (—39%) 0.0027 
CAPSIT OFF 29 r 7 (—26%) 0.0491 29 r 9 (—26%) 0.0012 31 r 8 (—21%) 0.0491 
Stand,Wa1k, Sit ON 15 r 1 (—32%) i 14 r 1 (—36%) i 14 r 1 (—32%) i 
CAPSIT OFF 12 r 2 (—43%) 0.0037 10 r 2 (—44%) <.0001 14 r 3 (—22%) 0.0009 
Contra-lateral ON 9 r 1 (—31%) <.0001 8 r 2 (—38%) <0.0001 10 r 2 (—23%) 0.0010 
Hand/Arm 
CAPSIT OFF 10 r 1 (—33%) <.0001 9 r 1 (—40%) <0.0001 11 r 1 (—27%) 0.0004 
Ipsilateral ON 8 r 1 (—33%) <.0001 8 r 1 (—33%) <0.0001 8 r 1 (—33%) <.0001 
Hand/Arm 
Baseline UPDRS scores for each patient are the means ofthree pre-GDNF determinations at —1 , +1 and +4 weeks following catheter 
implantation. UPDRS measures are means i SEM. CAPSIT measures are in seconds i SEM. 
*P value for comparing response across time. 
P values for post hoc comparisons: + 8 weeks vs. baseline; ++ 16 weeks vs. baseline; +++ 24 weeks vs. baseline; ++++ washout vs. 
baseline 
six hours after the subject’s ?rst dose of anti-PD medic ation 
for the day. These improvements were maintained over the 
?ve weeks after discontinuation of the highest-dose infusion 
(30 mcg/ day). The 95% con?dence intervals (CI) for % 
change from baseline at 24 weeks are given in Table 4, which 
support the clinical signi?cance of the GDNF effects at 24 
weeks. UPDRS (Part III) Motor scores in OFF were also 
signi?cantly improved by 13, 20, and 30% at 8, 16, and 24 
weeks post-GDNF, respectively. UPDRS Motor scores in ON 
were seen to be signi?cantly improved by 35, 30, and 30% at 
8, 16, and 24 weeks post-GDNF, respectively. The 95% con 
?dence intervals (CI) for % change from baseline at 24 weeks 
55 
60 
TABLE 4 
95% Con?dence intervals after 24 weeks of GDNF therapy 
95% CI 
Endpoint State % Improvement Low High 
Total UPDRS Off 33% 18% 47% 
Total UPDRS On 34% 1 6% 51% 
Motor UPDRS Off 30% 15% 48% 
Motor UPDRS On 30% 5% 61% 
Con?dence intervals for percent change from baseline to 
are given in Table 4, which support the clinical signi?cance of 65 improvement in Table 4 at 24 weeks, 
the GDNF effects at 24 weeks. UPDRS Motor scores 
remained signi?cantly improved in OFF and ON after wash 
the site of intraputamenal infusion, with signi?cant improve 
ments ranging from 31-44% at 16 and 24 weeks post-GDNF. 
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Safety and Side Effects 
The unilateral pump implantation procedure was safe, with 
few adverse events reported by all ten patients (Table 2). 
There was general discomfort from the pump, which was 
experienced by all ten subjects immediately following sur 
gery and sporadically thereafter. All patients experienced 
headaches the day following surgery, which resolved and did 
not reoccur. The MRI changes consisted of a halo of increased 
signal intensity on T2-weighted images less than 1 cm in 
thickness around the catheter. There was no change in body 
weight during the trial. Adverse event frequencies were: cath 
eter re-placement (1/ 10), infection (0/10), pump failure 
(0/ 10), hemorrhage (0/ 10), blood chemistry abnormalities 
(0/ 10) and delivery system complications/disconnections 
(0/ 10). Two subjects reported transient Lhermitte’s symp 
toms on 1-2 occasions. None of the subjects reported nausea, 
anorexia, vomiting or weight change as was seen by Nutt, et 
al., (2003). In addition, none of our ten subjects experienced 
hyponatraemia or alterations in antidiuretic hormone (ADH). 
The sustained improvements in all ten subjects are consis 
tent with extensive preclinical data suggesting GDNF e?i 
cacy in treating PD. The 95% con?dence limits for the total 
and motor UPDRS scores in ON and OFF further support the 
clinical signi?cance of the results. Decreases over baseline in 
the total and motor UPDRS scores after one-month washout 
indicate that the positive effects of GDNF may persist for at 
least four weeks after GDNF withdrawal. However, these 
persistent gains may be less in magnitude compared to the 
maximum bene?t observed during active GDNF infusion. 
This is consistent with prior studies in animal models of PD 
(Grondin, R., et al., (2002); Grondin, R., et al., (2003), 
Hebert, M. A., (1997)). 
Sustained and consistent placebo effects do not typically 
occur in PD subjects (14, 15) and patients with PD do not 
spontaneously improve over time making these confounds 
less likely explanations for the time course of improvements 
we observed. Strikingly, signi?cant effects were observed in 
all subjects receiving intraputamenal infusion of GDNF. Such 
consistent effects have not been seen in other treatments for 
PD such as DBS or fetal cell transplants (Krack, P., et al., 
Five-year follow-up of bilateral stimulation of the subtha 
lamic nucleus in advanced Parkinson’s disease, N. Engl. J. 
Med., 349: 1925-1 934 (2003); Olanow, C. W., et al., A double 
blind controlled trial of bilateral fetal nigral transplantation in 
Parkinson’s disease,Ann. Neurol. 54:403-414 (2003)). Eight 
subjects in this study showed improved postural stability, six 
of the ten patients had improved speech (reduced hypopho 
nia) and seven patients exhibited decreased hypomimia. The 
quality of ON time was improved by decreased symptom 
?uctuations in seven subjects. While dyskinesias were not 
prominent in this patient group, they were reduced in three 
subjects. All of the patients also reported an increased sense 
of well-being (manuscript in preparation), suggesting an 
additional effect of intraputamenal GDNF. 
Example 2 
Treatment of Parkinson’s Disease in Humans with 
Convection-Enhanced Infusion of GDNF into the 
Putamen 
Study Design 
Five patients with idiopathic, L-dopa responsive PD who 
were poorly controlled on optimal medical therapy were 
identi?ed. The ?rst patient (P1) had predominantly unilateral 
disease affecting the left side and underwent contralateral 
putamenal implantation of catheter and pump for r-metH 
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uGDNF delivery. The remaining patients (P2-5) had bilateral 
disease and bilateral putamenal implantations of delivery sys 
tems. The precise region of the dorsal putamen to be targeted 
for infusion was determined by co-localization studies using 
18F-dopa PET and MR images. Under MRI guidance, single 
port catheters were placed into the dorsal putamen, the site of 
maximal loss of 18F-?uorodopa signal (con?rmed by PET in 
all subjects). Pump placement and stereotactic surgery were 
tolerated well by all patients. However, there were some 
complications. P1 required perioperative repositioning of the 
catheter to center exactly within the dorsal putamen. This was 
achieved successfully on a second pass during the surgical 
procedure. In addition, patient 4 developed a wound infection 
related to the pumps and connection tubing that was success 
fully treated with explantation of the extracranial devices, 
antibiotics and re-implantation within 4 weeks. 
Patients 
Five PD patients were included in this pilot study. Ethical 
approval was obtained from the local ethics committees both 
at Frenchay Hospital and the Hammersmith Hospitals Trusts 
and all participants signed full consent forms. All patients 
were diagnosed as suffering from idiopathic PD according to 
standard criteria (brain bank criteria). Patients were selected 
for surgery when they were suffering signi?cant functional 
impairment despite optimal medical therapy. Exclusion cri 
teria included women of child-bearing age, age over 65, the 
presence of clinically signi?cant depression, or systemic dis 
ease or inability or unwillingness to comply with long-term 
follow-up. 
Surgery 
Sub cortical nuclei were localized and targeted using high 
resolution MR images acquired under strict stereotactic con 
ditions. Under general anesthesia, a modi?ed Leksell stereo 
tactic frame was a?ixed parallel to the orbito-meatal plane. 
The anterior (AC) and posterior (PC) commisures were iden 
ti?ed in a mid-sagittal planning scan. Axial images 2 mm 
thick were acquired parallel to the AC-PC plane and coronal 
images orthogonal to these then obtained. Using magni?ed 
hard copies of the MRI scans the inversion recovery scans 
were overlaid with the inverted T2 images to enhance the 
de?nition of the putamenal boundaries in both planes. Using 
the PET images, the area of the postero-dorsal putamen with 
the lowest 18F-dopa uptake was targeted for infusion; stereo 
tactic target coordinates were recorded and a trajectory 
planned. The following day, surgery was performed under 
general anesthesia. Under stereotactic conditions, 1 mm 
diameter guide tubes were implanted to a point above the 
putamen target over a guide rod. A 0.6 mm guide wire was 
introduced down the guide tube to target, following which the 
patients underwent repeat MR/CT imaging to verify target 
localization. The guide wire was then replaced with a 0.6 mm 
diameter catheter introduced to target. r-metHuGDNF 
primed SynchroMed pumps (Medtronic Inc, Minneapolis) 
were implanted in the upper abdominal region, subcutane 
ously in the ?rst patient, and subfascially (beneath the ante 
rior rectus sheath) in the subsequent cases; subfascial place 
ment reduced the pump pro?le in the abdomen and improved 
cosmetic appearance. Catheters were tunneled connecting the 
pumps to the indwelling 0.6 mm intraparenchymal brain cath 
eters. 
Convection-enhanced infusion into the targetted brain tis 
sue was achieved in this study by pumping drug at a relatively 
high rate through the smallest possible catheter having a 
single port at its distal end. Otherwise, drug emerging from a 
single port in the distal end would tend to travel up the path of 
least resistance, i.e., up the catheter/tissue interface. Because 
the ?ow up this space is proportional to the radius squared, 
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even small increases in catheter size would be expected to 
reduce the resistance outside the catheter, therefore reducing 
the pressure gradient and bulk ?ow into the tissue substan 
tially. Additionally, the smallest possible catheter is preferred 
since catheter placement would be expected to cause tissue 
trauma and local necrosis resistance to ?ow would be lower 
along the catheter tract. Therefore, it follows that a smaller 
catheter would result in less tissue damage and less drug 
?owing back along the catheter tissue interface to the cortex 
and entering the CSF space. On the other hand, with larger 
catheters and slower infusion rates, ?uid penetration into the 
tissues becomes solely dependent upon diffusion down a 
concentration gradient, which due to the size of the GDNF 
molecule will be very limited. This is supported by Chen et al. 
(J. Neurosurg 90:315-320, 1999isee appendix), who dem 
onstrate in a rat model that infusing protein into the striatum 
with a 0.4 mm catheter results in 5% loss of infusate through 
leak back along the catheter, and by increasing the diameter to 
0.6 mm, the loss increases to 35%. In this study, increasing the 
infusion rate beyond about 6 pl per hour, increased leak back 
and loss of infusate and infusate concentration had no effect 
on the volume of distribution. 
r-metHuGDNF Production and Infusion 
Recombinant-methionyl human glial cell line-derived neu 
rotrophic factor (r-metHuGDNF) was prepared by Amgen 
Inc. This protein was produced in Escherichia c0li cells that 
contain an expression plasmid with a DNA insert encoding 
mature human GDNF, with an addition of an amino terminal 
methionine. r-metHuGDNF is liquid formulated with 10 mM 
sodium citrate and 150 mM sodium chloride at a pH of 5.0. It 
was supplied in single-use vials at a concentration of 10 
mg/mL. Following implantation, the SynchroMed pumps 
were programmed to deliver a continuous infusion of 14.4 pg 
of r-metHuGDNF per putamen per day at rate of 6 pl per hour. 
The pumps were re?lled monthly with fresh solution. The low 
concentration of r-metHuGDNF was maintained for a period 
of 8 weeks. At 2 months the pumps were re?lled with fresh 
solution of higher concentration and programmed to deliver 
43.2 pg of r-metHuGDNF per putamen per day at a rate of 6 
pl per hour. Providing good tolerance and no side effects, this 
dose was to be maintained for the duration of the trial. How 
ever, due to the development of high-signal MRI changes of 
uncertain signi?cance, the infusion parameters were altered 
to deliver lower doses (10.8-14.4 pg of r-metHuGDNF) at 
lower rates (2-6 pl per hour), in attempt to establish safe and 
clinically effective parameters, with repeat MRI monitoring 
at regular intervals. Between 12 and 18 months, all patients 
received a continuous infusion of 14.4 pg of r-metHuGDNF 
per putamen per day at rate of 6 pl per hour. At 18 months the 
dose of GDNF was increased to 28.8 pg per putamen per day 
at rate of 6 pl per hour, and remained so until 24 months or 
longer except in P4 who reverted back to 14.4 pg at 20 
months. 
Clinical Evaluation and Follow-Up 
Clinical evaluations were based on the Core Assessment 
Program for Intracerebral Transplantations (CAPIT) (Lang 
ston, J . W. et al., Core assessment program for intracerebral 
transplantations (CAPIT). Mov Disord., 7, 2-13 (1992)) a 
validated protocol for evaluating surgical treatments of idio 
pathic PD. All patients were evaluated on the Uni?ed Parkin 
son’s Disease Rating Scale (UPDRS) and underwent timed 
motor tests at baseline, 3, 6, 12, 18 and 24 months. Assess 
ments were performed in both off and on medication states. 
Before they were assessed off medication, patients fasted and 
medications were withdrawn overnight. The same assess 
ments were then repeated after administration of L-dopa 
when the patients were “on”. 
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Health-Related Quality of Life Outcome Measurement and 
Follow-Up 
Patients were also assessed using validated quality of life 
questionnaires: the 39-item Parkinson’s Disease Question 
naire (PDQ 39) and the 36-item. Medical Outcomes Study 
short form health survey (SF-36) were used before surgery 
and after 3, 6, 12, 18, and 24 months. Descriptive statistics 
(mean, standard deviation, range, 95% con?dence interval) 
were obtained for each variable. Comparisons over time were 
made using Student’s paired-samples t test. 
Neuropsychological Evaluation and Follow-Up 
Also evaluated were changes in medication (L-dopa 
equivalents) requirement and neuropsychology, which con 
tained tests of verbal intellect, verbal and visual memory, 
attention, executive function, anxiety and depression as has 
been previously described (McCarter, R. 1., et al., Cognitive 
functioning after subthalamic nucleotomy for refractory Par 
kinson’s disease. J. Neurol. Neurosurg. Psychiatry, 69: 60-66 
(2000)). The battery of cognitive tests used was designed to 
minimize the possible confounding effects of both slowness 
of movement and movement dif?culty on cognitive test 
results. Friedman’s Related Samples test was used to evaluate 
the signi?cance of change over time in the rating scores. All 
analyses were performed in SPSS. Four of the patients (all of 
the bilateral cases) underwent pre-operative neuropsycho 
logical assessment. All ?ve patients were assessed at 12 and 
24 months post implantation. The signi?cance of changes in 
cognitive test performance was evaluated using con?dence 
intervals derived from the standard error of prediction around 
the predicted true score at baseline (Lord, F. M. and Novick, 
M. R. Statistical theories of mental test scores. Reading, MA: 
Addison-Wesley, (1968); Atkinson, L. Three standard errors 
of measurement and the Wechsler Memory ScaleiRevised. 
Psychological Assessment: A journal of consulting and clini 
calpsychology, 3:136 -138 (1991)). A signi?cant change was 
inferred if a score at either 12 or 24 months fell outside of the 
con?dence interval of the baseline score (for the unilateral 
case the baseline score was at 12 months and change scores 
were inferred for performance at 24 months). In addition, a 
PD control group consisting of 18 patients who had under 
gone other forrns of surgery for PD was used to establish the 
effect of repeat cognitive assessment over a 12 month period. 
For each patient in this group two postoperative neuropsy 
chological assessments were available. This control group 
was comparable with the GDNF patient group in terms of 
years of education, age at surgery, duration of PD at surgery 
and NART estimated FSIQ (p>0.05). 
Scanning Procedures and Image Analysis 
18F-dopa PET provides a measure of synaptic amino acid 
decarboxylase (AADC) activity and hence acts as an in vivo 
marker of dopamine storage and the functional integrity of 
dopamine terminals. Previous human and animal lesion stud 
ies have demonstrated that striatal 18F-dopa PET correlates 
with nigral cell numbers, dopamine content in striatal termi 
nals (Garnett, et al., Dopamine visualized in the basal ganglia 
of living man, Nature, 305: 137-138 (1983); Martin et al., 
Nigrostriatal function in humans studied with positron emis 
sion tomography. Annals 0fNeur0l0gy, 26:535-542 (1989); 
Brooks et al., Differing patterns of striatal 18F-dopa uptake in 
Parkinson’s disease, multiple system atrophy, and progres 
sive supranuclear palsy. Annals of Neurology, 28:547-555 
(1990b); Pate et al., Correlation of striatal ?uorodopa uptake 
in the MPTP monkey with dopaminergic indices. Annals of 
Neurology, 34: 331-338 (1993) and the UPDRS off medica 
tion (Morrish, et al., Measuring the rate of progression and 
estimating the preclinical period of Parkinson’s disease with 
[18F]dopa PET. Journal of Neurology, Neurosurgery & Psy 
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chialry, 64: 314-319 (1998)), in particular, with the bradyki 
nesia and rigidity sub scores (Otsuka, et al., Differences in the 
reduced 18F-Dopa uptakes of the caudate and the putamen in 
Parkinson’s disease: correlations with the three main symp 
toms, Journal of the Neurological Sciences, 136: 169-173 
(1996)). Furthermore, it is possible to demonstrate progres 
sive decline of striatal 18F-dopa uptake in patients with PD 
over time (Morrish, et al., 1998; Morrish, et al., An [18F] 
dopa-PET and clinical study of the rate of progression in 
Parkinson’s disease. Brain, 119 (Pt 2), 585-591 (1996)). 18F 
dopa PET was used here to assess striatal dopamine terminal 
function in ?ve PD patients receiving chronic intra-striatal 
GDNF infusions. 
The patients had 18F-dopa PET pre-operatively, and at 6, 
12, 18, and 24 months postoperatively using an ECAT 
EXACT RR++ camera (CTI/ Siemens 966; Knoxville, Tenn.) 
in 3D acquisition mode following withdrawal from medica 
tion for at least 12 hours. Patients received 150 mg of carbi 
dopa and 400 mg of entacapone; 1 hour later 111 MBq of 
1 8F -dopa in normal saline was administered as an intravenous 
bolus at the start of scanning. The images were acquired in 3D 
mode as 26 time frames over 94.5 minutes (1x30 seconds, 
4><1 min, 3><2 min, 3><3 min and 15><5 mins). Parametric 
images of 18F-dopa in?ux constants (Ki) were generated from 
time frames 25 .5 to 94.5 minutes post injection using in house 
software based on the MTGA approach of Patlak and Blas 
berg (Brooks, D. 1., The relationship between locomotor dis 
ability, autonomic dysfunction, and the integrity of the striatal 
dopaminergic system in patients with multiple system atro 
phy, pure autonomic failure, and Parkinson’s disease, studied 
with PET. Brain, 113 (Pt 5) 1539-1552 (1990a); Rakshi, J. S. 
et al., Frontal, midbrain and striatal dopaminergic function in 
early and advanced Parkinson’s disease A 3D [(18)F]dopa 
PET study. Brain, 122 (Pt 9): 1637-1650 (1999); Patlak, C. S. 
& Blasberg, R. G., Graphical evaluation of blood-to-brain 
transfer constants from multiple-time uptake data. Generali 
zations. J. Cereb. Blood Flow Metab, 5: 584-590 (1985)). 
Occipital counts from the same time frames were used to 
generate the tissue reference input function. Integrated 
images (time frames 25.5-94.5) were used to identify the 
parameters required to transform the Ki images into standard 
stereotaxic MNI space. The transformation matrix was then 
applied to the Ki images. After normalization a gaussian ?lter 
(6x6><6 mm) was applied. Mean voxel values of the normal 
ized Ki images were compared throughout the midbrain and 
basal ganglia at baseline, 6, and 12 months postoperatively 
using a paired Student’s t-test in SPM99 after application of 
a mask to eliminate cortical signals and so reduce the number 
of statistical comparisons.Any regional increases in 1 8F-dopa 
uptake could subsequently be de?ned as a volume of interest 
and the mean Ki values for those volumes extracted using the 
appropriate SPM tool (Brett, M., et al., Region of interest 
analysis using an SPM toolbox, Neurolmage, 16 (2002)). 
The integrated images were subsequently co-registered to 
each patient’s MRI scan for region of interest (ROI) analysis. 
All MRIs had been previously reformatted in the AC-PC 
plane. The subsequent transformation matrix was then 
applied to individual Ki images in order to transform them 
into the individual MRI space. Regions of interest (ROIs) 
were traced on the MRI and included the head of the caudate 
and the dorsal putamen which was divided into anterior and 
posterior halves. The position of the catheter tip was also 
calculated relative to the AC-PC line and an oval region of 
interest (6 mm><12 mm) centred at the tip location in the axial 
plane. The ROI was then copied onto 2 planes either side of 
the slice containing the calculated tip location, creating a 12 
mm><6 mm><5 mm (0.36 cc) volume of interest centered on the 
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catheter tip. The regions of interest were then used to sample 
18F activity on the parametric image. In the 4 patients oper 
ated on bilaterally, the mean Ki values for the left and right 
regions of interest were averaged to produce one Ki value for 
each of the ?ve ROIs per scan. Only the ROIs from the 
operated right side of the patient who received unilateral 
surgery were included in the analyses. The patient’s Ki values 
were then subjected to a paired Student’s two-tailed t test. 
Lack of Adverse Effects of r-metHuGDNF Infusion 
Surprisingly, side effects due to r-metHuGDNF infusion 
itself were very limited. There was no nausea, anorexia, vom 
iting or weight loss reported as in the previous intraventricu 
lar trial (Kordower, J. H. et al., 1999). There were no haema 
tological or blood chemistry abnormalities. At the high dose 
(43.2 ug/putamen/day), 3 subjects reported abnormalities of 
taste and smell (soapy or metallic), 2 subjects reported that 
their dreams had become abnormally vivid, and 4 subjects 
described a Lherrnitte’s phenomenon (tingling passing from 
the neck down through the arms and sometimes onto the trunk 
and down the legs provoked by neck ?exion). None of these 
effects necessitated immediate dose cessation or reduction, 
and all remitted (except for occasional, mild Lhennitte’ s sign) 
after the dose change discussed below that was instituted after 
the appearance of a high-density signal on MRI (end of month 
3). The Lherrnitte’s events were mild, intermittent, non-dis 
tressing; and mo st frequently occurred at the higher dose; and 
in fact it was often described as “pleasurable”. 
In all patients, T2 MR images showed a region of high 
signal intensity around the tips of the catheters. This response 
varied between patients, and even between the two hemi 
spheres in bilaterally implanted cases. The signal change was 
mo st evident following the dose escalation of r-metHuGDNF. 
Uncertainty as to the relevance of these changes, led to a 
reduction of r-metHuGDNF delivery back to 14.4 ug/puta 
men/ day for all patients between 3 and 6 months that resulted 
in a substantial reduction of the high signal. 
Ef?cacy of r-metHuGDNF Infusion 
Improvement in patients’ parkinsonian symptoms and 
signs were evident within 3 months of commencing the infu 
sion and continued to improve throughout the study. Patient 
diaries revealed that periods of severe immobility, one of the 
cardinal features of PD that occupied approximately 20% of 
the waking day prior to surgery, were eliminated completely 
by 6 months of r-metHuGDNF infusion. At 24-months dys 
kinesias were reduced signi?cantly by 73% in duration 
(p<0.05) and were all reported as mild in nature (Table 4). We 
observed mild dyskinesias in the practically de?ned off state 
in P4, who additionally reported short-lived infrequent early 
morning occurrences. These changes were not due to 
increases in medication. The study protocol aimed to main 
tain medication unchanged throughout the ?rst year of 
r-metHuGDNF treatment. However, P3 had been taking 
medication on demand due to frequent periods of akinesia at 
the inset of the study, and needed to reduce his medication as 
his symptoms improved. Patient P5 had increased sensitivity 
to L-dopa after GDNF infusion and also needed to reduce his 
dosage. The other 3 patients needed slight increases in their 
L-dopa equivalents intake. At 24 months, the mean daily dose 
of L-dopa equivalents was reduced by 26% (based on a for 
mula as designated by Pahwa, et. al. (Pahwa, R., et al., High 
frequency stimulation of the globus pallidus for the treatment 
ofParkinson’s disease, Neurology, 49: 249-253 (1997)). 
The most widely used and validated scale for assessing 
functional changes in PD is the Uni?ed Parkinson’s Disease 
Rating Scale (UPDRS). In all patients, the rate of symptom 
atic improvement was maximal in the ?rst 3 months of GDNF 
infusion and, thereafter, there was slower but sustained 





